Form 4: Cassava Sciences Director Michael J. O'Donnell Reports Stock Option Grant

Director Michael J. O'Donnell of Cassava Sciences Inc. reports the acquisition of stock options as part of the Non-employee Director Compensation Program.

Summary

• On May 9, 2024, Michael J. O'Donnell, a director of Cassava Sciences Inc., reported the acquisition of 10,000 stock options.
• The options were granted at an exercise price of $21.11.
• These options are part of the Non-employee Director Compensation Program approved by stockholders on May 4, 2023.
• The stock options vest over a one-year period, at a rate of 1/12 per month, and expire on May 9, 2034.

Sentiment

Score: 7

Explanation: The document reports a routine stock option grant to a director, which is generally viewed neutrally to positively as it aligns interests. There are no indications of negative news or concerns.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company over the next year.

Industry Context

Stock option grants are a common form of compensation for directors, aligning their interests with shareholders and incentivizing them to increase company value. This is a standard practice in publicly traded companies.

Comparison to Industry Standards

• Director compensation packages vary widely across the biotechnology industry, but stock options are a common component.
• Companies like Biogen and Amgen also use stock options as part of their director compensation, with vesting schedules typically ranging from one to four years.
• The specific number of options granted and the exercise price are usually determined based on the director's role, experience, and the company's performance.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• Employees are not directly impacted by this transaction.

Key Dates